Novartis AG Operating Expenses Growth & History (NVS)
Novartis AG's operating expenses was $25.33B for fiscal 2025.
View full Novartis AG company overviewNovartis AG annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $25.33B | $980.0M | +4.02% |
| 2024 | 2024-12-31 | $24.35B | −$68.0M | −0.28% |
| 2023 | 2023-12-31 | $24.42B | $486.0M | +2.03% |
| 2022 | 2022-12-31 | $23.93B | $1.75B | +7.89% |
| 2021 | 2021-12-31 | $22.18B | −$2.44B | −9.92% |
| 2020 | 2020-12-31 | $24.63B | −$541.0M | −2.15% |
| 2019 | 2019-12-31 | $25.17B | $1.98B | +8.54% |
| 2018 | 2018-12-31 | $23.19B | $2.12B | +10.05% |
| 2017 | 2017-12-31 | $21.07B | −$2.58B | −10.91% |
| 2016 | 2016-12-31 | $23.65B | — | — |
Novartis AG quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $6.49B | −$159.0M | −2.39% |
| Q1 2026 | 2026-03-31 | $5.83B | — | — |
| Q4 2025 | 2025-12-31 | $6.63B | — | — |
| Q3 2025 | 2025-09-30 | $6.32B | — | — |
| Q2 2025 | 2025-06-30 | $6.65B | $965.0M | +16.97% |
| Q2 2024 | 2024-06-30 | $5.68B | $89.0M | +1.59% |
| Q2 2023 | 2023-06-30 | $5.60B | −$1.51B | −21.25% |
| Q2 2022 | 2022-06-30 | $7.11B | $1.21B | +20.42% |
| Q2 2021 | 2021-06-30 | $5.90B | $60.0M | +1.03% |
| Q2 2020 | 2020-06-30 | $5.84B | −$114.0M | −1.91% |
| Q2 2019 | 2019-06-30 | $5.96B | $291.0M | +5.14% |
| Q2 2018 | 2018-06-30 | $5.66B | −$292.0M | −4.90% |
| Q2 2017 | 2017-06-30 | $5.96B | — | — |
Novartis AG operating expenses trends
Over the last five fiscal years, Novartis AG's operating expenses increased from $24.63B to $25.33B, a change of $706.0M. The latest reported quarter, Q2 2026, shows $6.49B.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novartis AG source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...